The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes

Shyamala C. Navada, Lewis R. Silverman

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Introduction: Hypomethylating agents (HMAs) are the standard of care for patients with higher-risk myelodysplastic syndromes (MDS), but patients who relapse or are refractory have a poor prognosis with an estimated survival of 4–6 months. Rigosertib, a Ras mimetic that inhibits the phophoinositide 3-kinase and polo-like kinase pathways, has been tested in patients with higher-risk MDS following treatment with HMAs, where there are no approved second-line therapies. Areas covered: This review will provide an overview of rigosertib, including safety and efficacy demonstrated in clinical trials. Expert commentary: There is an urgent need for new treatment options for patients who have failed or progressed on HMAs. Rigosertib is currently undergoing testing as a single agent in certain subsets of higher-risk MDS patients as well as in combination with azacitidine, where preliminary data show efficacy in patients with de novo MDS as well as HMA failures.

Original languageEnglish
Pages (from-to)805-810
Number of pages6
JournalExpert Review of Anticancer Therapy
Issue number8
StatePublished - 2 Aug 2016


  • DNA methyltransferase inhibitors
  • Myelodysplastic syndromes
  • ON 0910.Na
  • Ras-binding domain
  • hypomethylating agents
  • phosphatidylinositol 3-kinase
  • polo-like kinase
  • rigosertib


Dive into the research topics of 'The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this